Early access program launches to support ultrasensitive research into molecular residual disease and tumor evolution.

New chemistry is optimized for highest possible accuracy, with reproducible detection of ctDNA at 2.5 parts per million levels with low sample input (10 nanograms) in representative studies

SAN DIEGO, Nov. 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced an expansion of its molecular residual disease (MRD) research portfolio with an early access program for an ultrasensitive sequencing workflow. Designed to detect trace amounts of circulating tumor DNA (ctDNA) in plasma samples, the workflow's duplex chemistry analyzes both strands of a DNA molecule to increase confidence in detection. It combines the latest sequencing and software advances from the NovaSeq X platform and DRAGEN bioinformatics software to support longitudinal, whole-genome studies of MRD.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.